Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Frequent triptan use: observations on safety issues.

L Robbins1

  • 1Department of Neurology, Rush Medical College, Chicago, Ill. 60062, USA.

Headache
|February 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor.

International journal of obesity (2005)·2016
Same author

Risk-reducing surgery in FAP: role for surgeons beyond the incision.

Journal of surgical oncology·2010
Same author

Results of intervention for lupus patients with self-perceived cognitive difficulties.

Neurology·2005
Same author

How do cancer patients who try to take control of their disease differ from those who do not?

European journal of cancer care·2004
Same author

Quality of life in paediatric lupus.

Lupus·2004
Same author

Measuring recovery after a hip fracture using the SF-36 and Cummings scales.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2002
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
Same journal

American Headache Society 68th Annual Scientific Meeting June 4-7, 2026, Orlando, Florida.

Headache·2026
Same journal

In Memoriam-Doctor J. Keith Campbell.

Headache·2026
Same journal

Hypothalamus as a conductor of the migraine prodrome: A narrative review.

Headache·2026
Same journal

New academic year in Headache.

Headache·2026
Same journal

Essential readings in headache medicine: Top 10 educational articles from 2025.

Headache·2026
See all related articles

Frequent triptan use over extended periods appears relatively safe for patients with refractory migraine and chronic daily headache, with minimal adverse events observed in this study. This research supports the long-term cardiac safety of triptans.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Triptans are effective for refractory migraine and chronic daily headache.
  • Long-term safety data for frequent triptan use is limited.
  • Understanding the safety profile is crucial for managing chronic headache disorders.

Purpose of the Study:

  • To evaluate the cardiac and hematologic safety of frequent triptan use over extended periods.
  • To assess adverse events associated with long-term triptan utilization.
  • To provide evidence for the safe management of chronic migraine patients.

Main Methods:

  • Retrospective study of 118 patients with refractory migraine and chronic daily headache.
  • Inclusion criteria: triptan use ≥4 days/week for ≥6 months.

Related Experiment Videos

  • Evaluated cardiac safety (ECG, echocardiography, stress tests) and hematologic parameters.

    • Main Results:

    • No hematologic abnormalities were attributed to triptan use.
    • Electrocardiograms and cardiac stress tests showed normal findings.
    • Cardiac echocardiography revealed abnormalities in 10 patients, none related to triptans.
    • Adverse events were minimal, including fatigue and mild chest tightness.

    Conclusions:

    • Frequent triptan use over extended periods appears to be relatively safe for patients with refractory migraine and chronic daily headache.
    • The study found no significant cardiac or hematologic safety concerns.
    • Minimal adverse events suggest a favorable safety profile for long-term triptan therapy.